Go Deep
Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -19,056 | -2.0 | -4.29 | -0.11 | 264.90 |
| Oct 2026 | -19,422 | -2.2 | -4.70 | -0.11 | 290.58 |
| Oct 2026 | -19,354 | -2.0 | -4.62 | -0.11 | 285.09 |
| Oct 2026 | -19,191 | -1.9 | -4.44 | -0.11 | 274.02 |
| Oct 2026 | -19,381 | -2.0 | -4.66 | -0.11 | 287.29 |
| Oct 2026 | -19,368 | -2.0 | -4.64 | -0.11 | 285.64 |
| Oct 2026 | -19,123 | -1.9 | -4.36 | -0.11 | 268.07 |
Insight Molecular Diagnostics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 239,000.0 | 32,000.0 | 1,139,000.0 | 260,000.0 |
| Net Profit | -11,260,000.0 | -4,290,000.0 | -22,955,000.0 | -10,854,000.0 |
| EPS | -0.3 | -0.1 | -0.7 | -0.3 |
Insight Molecular Diagnostics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 4,055,000.0 | 1,881,000.0 | 1,503,000.0 | 958,000.0 | — |
| Net Profit | -50,222,000.0 | -60,663,000.0 | -27,781,000.0 | -72,902,000.0 | — |
| EPS | -1.6 | -4.7 | -3.8 | -20.0 | — |
Insight Molecular Diagnostics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 25,756,000.0 | 35,081,000.0 | 74,892,000.0 | 100,091,000.0 | — |
| Total Liabilities | 57,220,000.0 | 47,355,000.0 | 54,424,000.0 | 65,799,000.0 | — |
| Total Equity | -31,464,000.0 | -12,274,000.0 | 20,468,000.0 | 34,292,000.0 | — |
Owes vs Owns
Insight Molecular Diagnostics Inc. owed $1.72 for every $1 it owned in Jun 2026, up from $0.66 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.72× | 2.22× | 1.35× | 0.73× | 0.66× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Insight Molecular Diagnostics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 45.0%Receivables 4.4%Inventory 1.7%Fixed assets (tangible) 35.9%Other assets 13.0%
How it's funded — Dec 2025
Short-term debt 3.2%Long-term debt 3.0%Payables 4.4%Other liabilities 89.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 11.6 | 8.6 | 9.4 | 20.4 |
| Receivables | 1.1 | 1.6 | 0.5 | 2.0 |
| Inventory | 0.4 | 0.4 | 0.0 | 0.0 |
| Fixed assets (tangible) | 9.2 | 6.3 | 5.4 | 10.9 |
| Intangible assets | 0.0 | 14.6 | 56.6 | 61.6 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 3.3 | 3.5 | 2.9 | 5.2 |
| Liabilities & equity | ||||
| Short-term debt | 1.8 | 1.3 | 0.7 | 0.8 |
| Long-term debt | 1.7 | 2.4 | 2.2 | 2.7 |
| Payables | 2.5 | 1.6 | 1.0 | 1.3 |
| Other liabilities | 51.2 | 42.0 | 50.6 | 61.0 |
| Shareholders' equity | -31.5 | -12.3 | 20.5 | 34.3 |
| Net tangible assets | -31.5 | -26.9 | -36.1 | -27.3 |
Insight Molecular Diagnostics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -22,184,000.0 | -20,689,000.0 | -23,325,000.0 | -45,568,000.0 | — |
| Investing Activities | -3,185,000.0 | -512,000.0 | -932,000.0 | -4,340,000.0 | — |
| Financing Activities | 28,072,000.0 | 20,429,000.0 | 12,186,000.0 | 35,806,000.0 | — |